Manual chart review reveals bisphosphonate exposure misclassification in atypical femur fracture patients: auditing medical records in two international cohorts

We examined if inaccuracies in reported BP treatment in two large cohorts could explain the wide discrepancy observed between different patient cohorts with atypical femur fractures. Assessing BP treatment through manual review of medical and pharmacy records increased the discrepancy, indicating that other factors likely contribute to the observed variation. PURPOSE: Variation in results across fracture studies can stem from differences in study design, case definitions, data sources and healthcare settings, but in atypical femur fracture (AFF) studies, the reported proportion of AFF patients without bisphosphonate (BP) exposure shows an exceptionally wide variation. We aimed to evaluate whether misclassification of BP exposure could explain this variability and hypothesized that manual review of medical records would narrow differences between cohorts. METHODS: This retrospective study examined two population-based AFF cohorts: one from Sweden and one from Kaiser Permanente Southern California (KPSC). The Swedish cohort included 172 patients, aged ≥ 55 years with AFFs diagnosed between 2008 and 2010, of whom 38 had no recorded BP use. The KPSC cohort included 306 patients, aged ≥ 50 years with AFFs diagnosed between 2007 and 2017, of whom 29 were classified as BP-naïve. Manual review of medical records and pharmacy data was performed to verify BP exposure status. RESULTS: In the Swedish cohort, manual review did not identify any additional BP exposure, leaving 38 of 172 patients classified as BP-naïve (22.1%). In contrast, in the KPSC cohort, evidence of prior BP use was identified in 20 of 29 patients initially classified as BP-naïve, further reducing the proportion of BP-naïve AFF cases from 9.5 to 2.9%. CONCLUSION: Misclassification of BP exposure occurs and can substantially affect reported rates of BP-naïve AFF, but it does not fully explain the wide variation observed across studies. Additional contextual or methodological factors likely contribute and should be addressed in future AFF research.

Authors

Institutions

Publication Details

Journal
Osteoporosis International
Published
2026-07-28
DOI
https://doi.org/10.1007/s00198-026-08144-w
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Manual chart review reveals bisphosphonate exposure misclassification in atypical femur fracture patients: auditing medical records in two international cohorts

Hans Peter Bögl, Douglas C. Bauer, Denison S Ryan, Daphne Wezenberg et al.
Osteoporosis International
Bone health and osteoporosis research
article

Manual chart review reveals bisphosphonate exposure misclassification in atypical femur fracture patients: auditing medical records in two international cohorts

Hans Peter Bögl, Douglas C. Bauer, Denison S Ryan, Daphne Wezenberg, Johan Lyth, Annette L. Adams, Anna Spångéus, Jörg Schilcher, Austin Thompson, Alec Gilfillan, Rickard Sand, Dennis M. Black
article en

Abstract

We examined if inaccuracies in reported BP treatment in two large cohorts could explain the wide discrepancy observed between different patient cohorts with atypical femur fractures. Assessing BP treatment through manual review of medical and pharmacy records increased the discrepancy, indicating that other factors likely contribute to the observed variation. PURPOSE: Variation in results across fracture studies can stem from differences in study design, case definitions, data sources and healthcare settings, but in atypical femur fracture (AFF) studies, the reported proportion of AFF patients without bisphosphonate (BP) exposure shows an exceptionally wide variation. We aimed to evaluate whether misclassification of BP exposure could explain this variability and hypothesized that manual review of medical records would narrow differences between cohorts. METHODS: This retrospective study examined two population-based AFF cohorts: one from Sweden and one from Kaiser Permanente Southern California (KPSC). The Swedish cohort included 172 patients, aged ≥ 55 years with AFFs diagnosed between 2008 and 2010, of whom 38 had no recorded BP use. The KPSC cohort included 306 patients, aged ≥ 50 years with AFFs diagnosed between 2007 and 2017, of whom 29 were classified as BP-naïve. Manual review of medical records and pharmacy data was performed to verify BP exposure status. RESULTS: In the Swedish cohort, manual review did not identify any additional BP exposure, leaving 38 of 172 patients classified as BP-naïve (22.1%). In contrast, in the KPSC cohort, evidence of prior BP use was identified in 20 of 29 patients initially classified as BP-naïve, further reducing the proportion of BP-naïve AFF cases from 9.5 to 2.9%. CONCLUSION: Misclassification of BP exposure occurs and can substantially affect reported rates of BP-naïve AFF, but it does not fully explain the wide variation observed across studies. Additional contextual or methodological factors likely contribute and should be addressed in future AFF research.

Osteoporosis International
Linköping University (SE), Kaiser Permanente (US), University of California, San Francisco (US), County Administrative Board (SE), University of Gävle (SE), Gävle Hospital (SE)
Openalex Percentile: Top 7%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.